[D-Arg6,Pro9-NEt]Salmon GnRH; (DES-GLY10,D-ARG6,PRO-NHET9)-LHRH (SALMON); Salmon gonadotropin releasing hormone D-arg6 analog ethyl amide; Atlpnet-LHRH

Goserelin is a synthetic decapeptide analogue of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity.

Alarelin Acetate is a novel and potent LH-RH agonist.

Relugolix (formerly TAK-385; TAK385; trade names: Orgovyx and Relumina) is a non-peptidyl and orally bioactive antagonist of gonadotropin-releasing hormone (GnRH) approved in 2020 for use in the treatment of prostate cancer in men and uterine fibroids in women.

Degarelix(also known as HSDB-7817) is a GnRH antagonist .

Degarelix acetate is a novel and potent synthetic peptide.

Cetrorelix mono-acetate (SB-75) is a novel, potent and synthetic gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM.

Abarelix is a novel and potent antagonist of naturally occurring gonadotropin-releasing hormone (GnRH).

Elagolix sodium (NBI56418; ABT-620; Orilissa), the sodium salt of Elagolix, is an orally bioavailable and small molecule antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM) approved on 7/23/2018 by FDA for the management of moderate to severe pain associated with endometriosis.

Elagolix (formerly NBI56418; ABT620; NBI-56418; ABT-620; trade name: Orilissa) is a potent, specific, orally bioavailable, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) used for pain management.